Biology

Carolina Partners with ChristianaCare Gene Editing Institute to Launch CRISPR in a Box™ Kits for High School Science Labs

Retrieved on: 
Tuesday, March 5, 2024

Leading school science supplier Carolina Biological Supply Company announced an exclusive partnership with the ChristianaCare Gene Editing Institute to manufacture and distribute an affordable CRISPR in a Box™.

Key Points: 
  • Leading school science supplier Carolina Biological Supply Company announced an exclusive partnership with the ChristianaCare Gene Editing Institute to manufacture and distribute an affordable CRISPR in a Box™.
  • Educators are invited to see downloadable images of the kit components, classroom use and company leaders on the Gene Editing Institute’s website .
  • “Carolina is proud to partner with the Gene Editing Institute to bring cutting-edge biotechnology into the hands of students,” said Mark Meszaros, vice-president, Core Product Management and Innovation, at Carolina Biological.
  • The Gene Editing Institute , a wholly owned subsidiary of ChristianaCare, is a worldwide leader in CRISPR gene editing technology and the only institute of its kind based within a community health care system.

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024

Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

Key Points: 
  • Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
  • The results we will present at the AACR Annual Meeting will highlight the preclinical differentiation of our two lead candidates, TUB-030 and TUB-040.
  • The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR journal, Cancer Research.
  • The company will issue a press release detailing the full preclinical data following the presentation at AACR.

Boundless Bio Announces Multiple Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024

Boundless Bio , a clinical-stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced multiple upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is being held April 5-10, 2024, in San Diego, CA.

Key Points: 
  • Boundless Bio , a clinical-stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced multiple upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is being held April 5-10, 2024, in San Diego, CA.
  • Details of the presentations are as follows:
    Title: Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications

4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer

Retrieved on: 
Monday, March 4, 2024

4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the appointment of Kimberly Lee, D.O.

Key Points: 
  • 4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the appointment of Kimberly Lee, D.O.
  • as Chief Business Officer and member of the executive management team.
  • “We are excited to welcome Kim to the team to maximize the potential of our pipeline and to drive strategic growth,” said Dr. Pablo Lapuerta, Chief Executive Officer and Co-founder of 4M Therapeutics.
  • Prior to that, she held the role of Chief Corporate Affairs Officer at Taysha Gene Therapies.

One Mind™ Accelerator Announces Second Cohort of Mental Health Startups

Retrieved on: 
Monday, March 4, 2024

One Mind™ , a leading mental health non-profit based in Napa Valley, CA, today announced the 2024 cohort of its flagship One Mind Accelerator program.

Key Points: 
  • One Mind™ , a leading mental health non-profit based in Napa Valley, CA, today announced the 2024 cohort of its flagship One Mind Accelerator program.
  • By supporting emerging companies through the Accelerator, One Mind seeks to positively impact the lives of people facing mental health challenges by advancing precision psychiatry, and making high quality mental healthcare more accessible, affordable, and equitable.
  • This is the second cohort for the One Mind Accelerator since the program’s launch in 2023.
  • Cerula Care is a virtual behavioral healthcare practice that partners with specialists and tailors behavioral health care for adults with serious illness.

Anagenex Expands Leadership Team with Appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer

Retrieved on: 
Monday, March 4, 2024

Anagenex , a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines, today announced the appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer.

Key Points: 
  • Anagenex , a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines, today announced the appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer.
  • “I am thrilled to welcome Adrian to Anagenex.
  • His groundbreaking AI enabled drug discovery experience will drive our platform capabilities to new heights as we work to further enhance our integrated AI and lab capabilities,” said Nicolas Tilmans, CEO of Anagenex.
  • Prior to joining Anagenex, he spent over a decade at Exscientia where he was a founding member of the team and went on to support the company through a successful IPO while building its AI team from scratch and eventually serving as the company’s Chief Technology Officer.

Best MCAT Prep Course (2024): Blueprint Prep & Magoosh Reviewed by Better Business Advice

Retrieved on: 
Friday, March 1, 2024

Better Business Advice, a prominent online platform providing business and consumer guidance, has released a comprehensive assessment of the top MCAT prep courses for the year 2024.

Key Points: 
  • Better Business Advice, a prominent online platform providing business and consumer guidance, has released a comprehensive assessment of the top MCAT prep courses for the year 2024.
  • The review highlights two leading MCAT prep companies: Blueprint Prep and Magoosh , both providing remarkable resources developed by academic experts.
  • Selecting the best MCAT prep course is paramount for optimizing preparation and attaining one’s desired score on the exam.
  • Better Business Advice provides a comprehensive review comparing the best MCAT prep courses which can be helpful for medical students planning to take the MCAT.

Harry K. Wong Publications Shares the Passing of Education Icon and Its Founder, Harry K. Wong

Retrieved on: 
Thursday, February 29, 2024

It is with the greatest sadness that Harry K. Wong Publications announces the passing of the legendary educator Dr. Harry K. Wong.

Key Points: 
  • It is with the greatest sadness that Harry K. Wong Publications announces the passing of the legendary educator Dr. Harry K. Wong.
  • View the full release here: https://www.businesswire.com/news/home/20240229182725/en/
    At the start of his career, it was difficult to tell Harry Wong from his high school students.
  • (Photo: Business Wire)
    A new teacher advocate, Harry K. Wong was passionate about helping teachers be the most effective they could be for their students.
  • Harry K. Wong was a colleague to all and a true friend of education.

Playground Global Promotes Benjamin Kim PhD to Partner

Retrieved on: 
Wednesday, February 28, 2024

Playground Global , an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner.

Key Points: 
  • Playground Global , an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner.
  • View the full release here: https://www.businesswire.com/news/home/20240228985705/en/
    Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University.
  • “It’s an honor to contribute to the Playground life sciences ecosystem and support our portfolio companies in evolving deeply technical breakthroughs into transformational businesses,” said Ben Kim, PhD, Partner at Playground.
  • “Ben brings an infectious passion for and incredible knowledge of bioengineering and biophysics to the Playground team,” said Jory Bell , General Partner at Playground.

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

Retrieved on: 
Wednesday, February 28, 2024

bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.
  • The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
  • As a Network partner, bit.bio’s ioCells portfolio of human cells for research and drug discovery can be integrated into Ginkgo’s platform ecosystem.
  • bit.bio’s ioCells products are precision reprogrammed from iPSCs using bit.bio’s opti-ox TM technology.